Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

(2023) Ohsang Kwon et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Baricitinib for the Treatment of Alopecia Areata

(2023) Egídio Freitas et al.   DRUGS

Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study

(2023) L. Gargiulo et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Two Phase 3 Trials of Baricitinib for Alopecia Areata

(2022) Brett King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Short‐term real‐world experience with baricitinib treatment in Danish adults with moderate–severe atopic dermatitis

(2022) Ida Vittrup et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata

(2020) Nekma Meah et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children, and their families

(2018) Lucy Y. Liu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Alopecia areata

(2017) C. Herbert Pratt et al.   Nature Reviews Disease Primers

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE